BTIG Reiterates Buy Rating on Boston Scientific (BSX) following Bolt Medical deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Deutsche Bank Upgrades Boston Scientific (BSX) to Buy
January 10, 2025 7:08 AM ESTDeutsche Bank analyst Pito Chickering upgraded Boston Scientific (NYSE: BSX) from Hold to Buy with a price target of $108.00 (from $87.00).
The analyst comments "So the BSX story has become simpler, and as one of the best-in-class medtech names, we believe BSX is poised again to outperform in 2025, and we are upgrading the shares to Buy with a $108 price target which is 34x our 2026E EPS. There are many risks to our Buy thesis: (1) BSX is one of the most consensus longs within our coverage universe. So who might be the... More
